Is Abiomed (ABMD) A Great Investment to Take?

Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return of 2.86% was recorded by the fund for the fourth quarter of 2021, beating its Benchmark, the MSCI All Country World Small Cap Index, which returned 2.22% for the same period. Spare some time to check the fund’s top 5 holdings to have a clue about their top bets for 2022.

Harding Loevner Global Small Companies Equity Fund, in its Q4 2021 investor letter, mentioned Abiomed, Inc. (NASDAQ: ABMD) and discussed its stance on the firm. Abiomed, Inc. is a Danvers, Massachusetts-based medical device company with a $14.3 billion market capitalization. ABMD delivered a -12.06% return since the beginning of the year, while its 12-month returns are up by 6.84%. The stock closed at $315.85 per share on March 02, 2022.

Here is what Harding Loevner Global Small Companies Equity Fund has to say about Abiomed, Inc. in its Q4 2021 investor letter:

“We have also found opportunities in medical device manufacturers. An example is Abiomed, a pioneer of cardiovascular surgical equipment, whose pumps are critical to the surgical treatment of heart disease. Like Simulations Plus, the company is applying Al algorithms to its unique trove of patient data to glean additional insights. Abiomed recently developed Impella Connect, a HIPAA-compliant, cloud-based remote-monitoring platform, which can offer physicians predictions, such as a patient’s expected arterial pressure or the probability a patient will recover native heart function. This product can help Abiomed become an even more important supplier to cardiologists, extending the company’s potential duration of growth.”

goodluz/Shutterstock.com

Our calculations show that Abiomed, Inc. (NASDAQ: ABMD) failed to obtain a mark on our list of the 30 Most Popular Stocks Among Hedge Funds. ABMD was in 23 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 25 funds in the previous quarter. Abiomed, Inc. (NASDAQ: ABMD) delivered a 1.09% return in the past 3 months.

In October 2021, we published an article that includes ABMD in the 5 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors. You can find more than 100 investor letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q4 page.

Disclosure: None. This article is originally published at Insider Monkey.